Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

BACKGROUND: We conducted a phase I, multicenter, open-label, dose-finding, and expansion study to determine the safety and preliminary efficacy of eprenetapopt (APR-246) combined with pembrolizumab in patients with advanced/metastatic solid tumors (ClinicalTrials.gov NCT04383938). PATIENTS AND METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, H., Shapiro, G.I., Gao, X., Mahipal, A., Starr, J., Furqan, M., Singh, P., Ahrorov, A., Gandhi, L., Ghosh, A., Hickman, D., Gallacher, P.D., Wennborg, A., Attar, E.C., Awad, M.M., Das, S., Dumbrava, E.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588880/
https://www.ncbi.nlm.nih.gov/pubmed/36084396
http://dx.doi.org/10.1016/j.esmoop.2022.100573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588880/
https://www.ncbi.nlm.nih.gov/pubmed/36084396
http://dx.doi.org/10.1016/j.esmoop.2022.100573

Ejemplares similares